Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis

Noemie Jourde-Chiche (1, 2, 3) , Elizabeth Whalen (4) , Bertrand Gondouin (1) , Cate Speake (4) , Vivian Gersuk (4) , Bertrand Dussol (5, 1) , Stéphane Burtey (5, 1) , Virginia Pascual (6) , Damien Chaussabel (7) , Laurent Chiche (8)

1 VRCM - Vascular research center of Marseille
2 Physiopathologie de l'Endothelium
3 LA CONCEPTION - Hôpital de la Conception [CHU - APHM]
4 Systems Immunology Laboratory
5 Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM]
6 BIIR - Baylor Institute for Immunology Research
7 Baylor Institute for Immunology Research (BIIR)
8 CIML - Centre d'Immunologie de Marseille - Luminy

Objective. LN is a severe complication of SLE. Non-invasive biomarkers are needed for identifying patients at risk of a renal flare, for differentiating proliferative from non-proliferative forms and for assessing prognoses for LN. Methods. We assessed the link between blood transcriptional signatures and LN using blood samples from patients with biopsy-proven LN, extra-renal SLE flares or quiescent SLE. Healthy controls, and control patients with glomerular diseases or bacterial sepsis were included. Modular repertoire analyses from microarray data were confirmed by PCR. Results. A modular neutrophil signature (upregulation of module M5.15) was present in 65% of SLE patients and was strongly associated with LN. M5.15 activity was stronger in LN than in extra-renal flares (88 vs 17%). M5.15 was neither correlated to IFN modules, nor to SLEDAI or anti-dsDNA antibodies, but moderately to CS dose. M5.15 activity was associated with severity of LN, was stronger when proliferative, and decreased in patients responding to treatment. M5.15 activation was not caused by higher CS dose because it correlated only moderately to neutrophil count and was also observed among quiescent patients. Among quiescent patients, those with a past history of LN had higher M5.15 activity (50 vs 8%). M5.15 activation was present in patients with bacterial sepsis or ANCA-associated vasculitis, but not in patients with other glomerular diseases. Overall, M5.15 activation was associated with past, present or future flares of LN. Conclusion. Modular neutrophil signature could be a biomarker for stratifying LN risk and for monitoring its response to treatment. Trial registration. ClinicalTrials.gov, http://clinicaltrials.gov, NCT00920114

Mots clés: systemic lupus erythematosus; biomarkers; neutrophil; gene expression; lupus nephritis

Domaines: Rhumatologie et système ostéo-articulaire; Urologie et Néphrologie; Génomique, Transcriptomique et Protéomique [q-bio.GN]

Noemie Jourde-Chiche, Elizabeth Whalen, Bertrand Gondouin, Cate Speake, Vivian Gersuk, et al.. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology, 2017, 56 (3), pp.477-487. ⟨10.1093/rheumatology/kew439⟩. ⟨hal-01466039⟩